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  2  
ABS TRA CT  24  
Biochem ic al  and  genet ic  evi dence  im pli cate  soluble  oli gomeric  amyl oid - beta  $ȕR i n  25  
tr iggering  $O]KHLPHU¶V disea se  (AD)  pathophysiol ogy.   Moreover,  const itutive  deletion  of  the  26  
A ȕo - binding  cel lul ar  prion  prote in  (PrP C )  preven t s  devel opment  of  me mory  defi cits  i n  27  
APP sw e 36¨( mi ce,  a  model  of  familial  AD.  He re,  we  defi ne  the  role  of  PrP
C
 t o  res cue  or  halt  28  
est ablished  AD  endo phenotypes  i n  a  the rapeuti c  diseas e - modi fying  t i m e  windo w  af te r  29  
sym ptom  onset .   Deletion  of  Prnp  at  eit her  12  or  16  months  of  age  full y  reve rses  hippocampal  30  
synapse  loss ,  and  com plet ely  res cues  pre - existing  behavioral  defi cit s  by  17  mont hs .  I n  contr ast ,  31  
but  consi stent  wit h  a  neuronal  functi on  for  A ȕo/PrP C  signal ing,  plaque  density,  microgliosis  32  
an d  a str ocytos is  are  not  alt ered.  Degeneration  of  cat echolami nergic  neurons  was  unchanged  by  33  
PrP
C
 reduct ion  aft er  disea se  onset.  These  res ults  defi ne  the  potent ial  of  tar geting  PrP
C
 a s  a  34  
disea se - modif ying  therapy  for  certain  AD - rel ate d  phenotypes  aft er  disease  onset .   35  
 36  
Ke ywords:  $O]KHLPHU¶V dise ase;  cellula r  prion  prote in;  ta moxifen  induci ble  Cre - lox  syste m  37  
Abbrevi ati ons:  APP Sw e /PS1 E¨9  =  Amyloi d  pre cur sor  prot ein  with  famil ia l  Swedish  38  
mutati on/Presenilin  1  exon  9  del et ion;   A ȕ =  a myloid - beta;  A ȕo  =  a my loi d - bet a  oligo mer s;  PrP C  =  39  
cel lula r  pri on  prot ein;  Prnp  =  pri on  gene  name  40  
 41  
SI GNIFI CANC E  S TATEME NT  42  
The  study  pre sented  here  further  el uci dates  our  under sta nding  of  the  A ȕo - PrP C  signali ng  pat hway  i n  43  
a  fa mil ia l  form  o f  $O]KHLPHU¶V dise ase  (AD)  by  impli cating  PrP C  a s  a  potent ial  therapeut ic  ta rget  for  44  
AD .  I n  par ti cula r,  genet ic  del eti on  of  Prnp  re scue d  sever al  fami li al  AD  (FAD)  ass ociated  45  
  3  
phenot ypes  after  disease  onset  i n  a  mous e  m od el  of  FAD.  This  study  under scores  the  therapeutic  46  
pote ntia l  of  PrP
C
 del etion  give n  that  pat ie nts  alr eady  pre sent  sympto ms  a t  the  time  of  dia gnosi s.   47  
 48  
INTROD UCTION  49  
$O]KHLPHU¶V dise ase  (AD)  i s  the  most  commo n  for m  o f  dement ia  wor ldwide  wi t h  more  tha n  5  50  
mil li on  Amer ican s  with  the  disease  (Alz hei mer 's,  2012) .  A D  i s  char acterized  by  two  hal lmar k  51  
pat hologies:  a myloi d - ȕ $ȕ pla ques  co mposed  of  $ȕ pepti de  and  neurofibr illar y  tangle s  comp osed  52  
of  hyper phosphor ylated  Tau  (Bra ak  and  Braak,  1991;  Selkoe ,  2011) .  The  cl inic al  pre sent ation  of  AD  53  
i s  characte rized  by  progre ssi ve  memory  loss  and  early  deat h  (M olsa  e t  al.,  1986;  Maye ux,  2003) .  54  
Centra l  t o  AD  i s  the  ina bil ity  of  pat ie nts  t o  form  new  me mor ie s ,  with  synapti c  dysfuncti on  and  loss  55  
bei ng  ti ghtly  cor related  with  symp tom  progr ess ion  (Selkoe,  2002;  Scheff  e t  al .,  2006) .  Thu s  56  
under sta nding  how  synaps es  ar e  lost  i s  key  t o  under sta nding  AD.  Geneti c  and  bioc hemic al  evi dence  57  
sugges t  a  solubl e  high - mole cul ar  weight  oli go mer ic  amy loi d - ȕ peptide  $ȕR as  a  tr igger  for  58  
synapt ic  dysfuncti on  i n  AD  (Har dy  and  Selkoe,  2002;  Sheng  e t  al .,  2012;  Dohler  et  al .,  2014;  59  
Kostyl ev  e t  al .,  2015) .  Sever al  studies  i n  rode nt  models  have  shown  tha t  $ȕR c a n  ini tiate  a  cas cade  60  
of  del et eri ous  effect s  on  synaptic  function  (Lamber t  e t  al .,  1998;  Wal sh  e t  al.,  2002;  Lesne  e t  al .,  61  
2006;  Shankar  e t  al.,  2008) .  These  studies  highlight  the  import ance  of  under sta nding  $ȕR- dependent  62  
synapt otoxicity.   63  
 64  
Recent  evi dence  suggests  PrP
C
 a s  a  cent ral  protein  i n  medi at ing  synapt otoxic ity.  Previous  work  has  65  
shown  PrP
C
 a s  a  high - affini ty  binding  par tne r  of  $ȕR and  medi at or  i n  suppr essing  LTP  (Laur en  e t  66  
al .,  2009) .  Additi onall y,  cons t itutive  del eti on  of  Prnp  c a n  re scue  synapse  density,  sur vival,  and  67  
le ar ning  and  me mory  de ficit s  s e e n  in  a  mouse  model  of  fa mil ia l  AD  ( Gi mbel  e t  al .,  2010) .  Other  68  
  4  
groups  have  shown  PrP
C  
t o  bind  $ȕR with  high  affini ty  (Chen  e t  al .,  201 0;  Dohler  e t  al.,  2014) ,  t o  69  
medi at e  suppr ess ion  of  LTP  (Bar ry  e t  al.,  2011;  Frei r  e t  al .,  2011;  Klyubin  e t  al .,  2014) ,  and  suppre ss  70  
le ar ning  and  me mory  (C hung  e t  al .,  2010;  Fluhar ty  e t  al .,  2013) .  Nevert hel ess ,  conflicting  re port s  o f  71  
the  role  for  PrP
C
 i n  med ia ting  synaptot oxici ty  (Bal ducci  e t  al .,  2010;  Cal ella  et  al.,  2010;  Kessels  et  72  
al .,  2010)  have  prompte d  further  studies  t o  te st  the  the rapeutic  pote ntia l  of  PrP
C
 a s  a  target .  73  
 74  
Targe tin g  PrP
C
 for  A D  tr eatment  holds  the  potent ial  for  dise ase - modifying  the ra py,  a s  opposed  t o  75  
the  sympto mat ic  act io n  of  cur re nt  inte rve nti ons  appr o ved  for  AD  (Yia nnopoulou  and  Papageorgiou,  76  
2013) .  Severa l  studies  have  shown  dir ectly  or  indi rectly  that  $ȕR binding  t o  PrP C  le ads  t o  PrP C -77  
mGluR5  co upli ng  (Um  e t  al.,  2013;  Haas  et  al .,  2015)  and  subse quent  activati on  of  int ra cell ular  78  
component s  inc luding  eEF2  (U m  e t  al .,  2013;  M a  e t  al .,  2014)  and  Fyn  (Lar son  e t  al .,  2012;  U m  e t  79  
al .,  2012;  Rushwort h  e t  al .,  2013;  Kauf man  e t  al.,  2015)  c a n  le ad  t o  dendri tic  spine  loss  (Um  e t  al .,  80  
2012;  Zhang  e t  al .,  2015) ,  suppr ess ed  synapt ic  plasti cit y  (Hu  et  al .,  2014;  Haas  e t  al .,  2015) ,  and  Tau  81  
phosphor ylation  (Larson  e t  al.,  2012;  Kaufman  e t  al .,  2015) .  Mul ti ple  groups  have  begun  t o  develop  82  
met hods  t o  ta rge t  the  $ȕR- PrP C  int eracti on  using  smal l  mole cul e  appr oaches  (Fluh arty  e t  al.,  2013;  83  
Ai mi  e t  al.,  2015;  Osborne  e t  al .,  2016)  and  immunothera py  appr oaches  (Chung  e t  al .,  2010;  Bar ry  et  84  
al .,  2011) .  These  efforts  under score  the  need  t o  understand  whether  the  $ȕR- PrP C  intera cti on  i s  85  
re quired  for  AD  phenot ype  mai nte nance  and  progre ssi on  after  dise ase  onset .   86  
 87  
I n  orde r  t o  te st  the  ther apeutic  pote ntia l  of  targeting  Prnp ,  we  deci ded  t o  ta ke  advant age  of  a  88  
ta moxifen  (TMX)  induci ble  Cre - lox  syst em  t o  par tiall y  dele te  Prnp  e arl y  after  disease  onset ,  and  89  
months  after  disease  onset  i n  a  mo use  model  of  fa mil ia l  AD.  Part ial  del etion  of  Prnp  was  able  t o  90  
  5  
re scue  synapti c  and  behavi oral  deficit s  i n  a  mou se  model  o f  AD  a t  12  an d  16  months .  These  re sult s  91  
highl ight  the  cl inic al  potentia l  of  ta rgeting  the  $ȕR- PrP C  interacti on.  92  
 93  
MATERI ALS  AND  METH O DS  94  
An imals  95  
All  mic e  we re  cared  for  by  the  Yale  Ani mal  Re sour ce  Center .  <DOH¶V insti tuti onal  animal  car e  and  96  
use  commit te e  appr oved  al l  exper iment s.  As  previousl y  descri bed  (Gimb el  e t  al .,  2010)  the  mouse  97  
str ains  used  were  the  APP swe 36(1¨( mic e  on  a  C57BL/6J  background,  and  the  ER - Cre  mic e  98  
(Hayas hi  and  McM ahon,  2002)  on  a  C57BL/6J  background  were  purc hase d  fro m  Jac kson  99  
Labora tory  (Bar  Harbor,  ME).  The  flox - Prnp  mice  on  a  C57Bl6  background  have  been  described  100  
(Tuzi  e t  al .,  2004;  Bradford  et  al.,  2009) .  All  exper iment s  utilize d  litt erma te  contr ol  mic e.  The  12MD  101  
cohor t  contained  a  2:1  mal e  t o  fe male  s e x  ra tio  while  the  16MD  cohor t  cont ai ned  a  1.1:1  mal e  t o  102  
fe mal e  s e x  ratio.  The  different ial  mal e  t o  fe mal e  s e x  ra tios  was  not  int entional  but  a  cause  of  ra ndom  103  
bre edi ng  and  sel ection.    104  
 105  
Brain  tissue  collection  106  
Immunohistology  107  
Mi ce  were  eutha nized  and  i mmedi at el y  per fused  with  ic e - cold  phosphat e  buffer  sal ine  (PBS)  for  two  108  
minut e s ,  followed  by  a  five - minut e  per fusion  with  ic e - cold  4%  par aformal dehyde  (PFA).  Brai ns  109  
were  dissected  out,  cut  down  the  midli ne  into  two  he misphe re s  and  fixed  for  24  hours  i n  4%  PFA.  110  
Foll owing  fixation,  brains  were  cut  int o  40  µ m  par asa git tal  sections  usi ng  a  Leic a  (Wet zl ar ,  111  
Germany)  WT1000S  Vi bratome.  Se ct ions  were  stor ed  i n  PBS  a t  4º C  until  staini ng.   112  
 113  
